Identifying HER2 in serum-derived exosomes from advanced gastric cancer patients represented a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab-based therapy (Li Q. et al., 2023). This evidence concerns the gene ERBB2 and gastric cancer.